Jul 13th 2012 - Edison Investment Research today published a report on Phytopharm (PYM.L, LSE:PYM, LON:PYM) entitled "Binary Vision". In summary, the report says:
Phytopharm’s investment case centres on a binary event in February 2013 when top-line results are expected from its Confident-PD Phase II trial of Cogane in early-stage Parkinson’s disease. Positive data could allow Phytopharm to secure a development and commercialisation partner for Cogane, milestones that would significantly increase our rNPV of £48m to £83m. A failure of Cogane in the Confident-PD study could reduce the company’s market value to cash or lower, although encouraging data in amyotrophic lateral sclerosis may offer an alternative route to market.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »